Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

ziftomenib

An orally bioavailable inhibitor of the menin-mixed lineage leukemia (MLL; myeloid/lymphoid leukemia; KMT2A) fusion protein, with potential antineoplastic activity. Upon oral administration, ziftomenib prevents the interaction between the two proteins menin and MLL, and thus the formation of the menin-MLL complex. This reduces the expression of downstream target genes and results in an inhibition of the proliferation of MLL-rearranged leukemic cells. The menin-MLL complex plays a key role in the survival, growth and proliferation of certain kinds of leukemia cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:menin-KMT2A inhibitor KO 539
menin-mixed lineage leukemia protein-protein interaction inhibitor KO 539
menin-MLL inhibitor KO-539
menin-MLL interaction inhibitor KO 539
Code name:KO 539
KO-539
KO539
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search